Risk of myocardial infarction related to factor v Leiden Mutation: A meta-analysis

Genetic Testing and Molecular Biomarkers

Volumn 14, Issue 4, 2010, Pages 493-498

  Dowaidar, Moataz ^a   Settin, Ahmad ^a  

^a QASSIM UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN;

ARTICLE; CARDIOVASCULAR RISK; DATA BASE; DATA EXTRACTION; GENE MUTATION; HEART INFARCTION; HUMAN; MUTATION RATE; STATISTICAL ANALYSIS;

BLOOD COAGULATION DISORDERS, INHERITED; CASE-CONTROL STUDIES; FACTOR V; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MYOCARDIAL INFARCTION; ODDS RATIO; POINT MUTATION; RISK FACTORS;

EID: 77955908209     PISSN: 19450265     EISSN: 19450257     Source Type: Journal    
DOI: 10.1089/gtmb.2010.0017     Document Type: Article

References (60)

1. Amowitz LL, Komaroff AL, Miletich JP, Ridker PM (1999) Factor V Leiden is not a risk factor for myocardial infarction among young women. Blood 93:1432-1433.
2. Araú jo F, Santos A, Araú jo V, et al. (1999) Genetic risk factors in acute coronary disease. Haemostasis 29:212-218.
3. Ardissino D, Peyvandi F, Merlini PA, et al. (1996) Factor V (Arg 506?Gln) mutation in young survivors of myocardial infarction. Thromb Haemost 75:701-702.
4. Avellone G, Di Garbo V, Di Raimondo D, et al. (2001) [Evaluation of resistance to activated protein C in myocardial infarction patients] Minerva Cardioangiol 49:363-368.
5. Baranovskaya S, Kudinov S, Fomicheva E, et al. (1998) Age as a risk factor for myocardial infarction in Leiden mutation carriers. Mol Genet Metab 64:155-157.
6. Bauduer F, Lacombe D (2005) Factor V Leiden, prothrombin 20210A, methylenetetrahydrofolate reductase 677T, and population genetics. Mol Genet Metab 86:91-99 (review).
7. Burzotta F, Paciaroni K, De Stefano V, et al. (2002) Increased prevalence of the G20210A prothrombin gene variant in acute coronary syndromes without metabolic or acquired risk factors or with limited extent of disease. Eur Heart J 23:26-30.
8. Celik S, Ovali E, Baykan M, et al. (2001) Factor V Leiden and its relation to left ventricular thrombus in acute myocardial infarction. Acta Cardiol 56:1-6. (Pubitemid 32267018)
9. Cripe LD, Moore KD, Kane WH (1992) Structure of the gene for human coagulation factor V. Biochemistry 31:3777-3785.
10. Cushman M, Rosendaal FR, Psaty BM, et al. (1998) Factor V Leiden is not a risk factor for arterial vascular disease in the elderly: Results from the Cardiovascular Health Study. Thromb Haemost 79:912-915.
11. Dacosta A, Tardy-Poncet B, Isaaz K, et al. (1998) Prevalence of factor V Leiden (APCR) and other inherited thrombophilias in young patients with myocardial infarction and normal coronary arteries. Heart 80:338-340.
12. de Paula Sabino A, Ribeiro DD, Carvalho MG, et al. (2006) Factor V Leiden and increased risk for arterial thrombotic disease in young Brazilian patients. Blood Coagul Fibrinolysis 17: 271-275.
13. Demarmels Biasiutti F, Merlo C, Furlan M, et al. (1995) No association of APC resistance with myocardial infarction. Blood Coagul Fibrinolysis 6:456-459.
14. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177-188.
15. Doggen CJ, Cats VM, Bertina RM, Rosendaal FR (1998) Interaction of coagulation defects and cardiovascular risk factors: increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A. Circulation 97:1037-1041.
16. Dönmez Y, Kanadasi M, Tanriverdi K, et al. (2004) Prothrombin 20210GA and factor V Leiden mutations in patients less than 55 years old with myocardial infarction. Jpn Heart J 45:505-512.
17. Dzimiri N, Meyer B (1996) World distribution of factor V Leiden. Lancet 347:481-482.
18. Emmerich J, Poirier O, Evans A, et al. (1995) Myocardial infarction, Arg 506 to Gln factor V mutation, and activated protein C resistance. Lancet 41345(8945):321.
19. Eritsland J, Gjønnes G, Sandset PM, et al. (1995) Activated protein C resistance and graft occlusion after coronary artery bypass surgery. Thromb Res 79:223-226.
20. Glueck CJ, Munjal J, Aregawi D, et al. (2007) Thrombophiliahypofibrinolysis and atherothrombotic cardiovascular disease
21. Grines CL, Cox DA, Stone GW, et al. (1999) Coronary angioplasty with or without stent implantation for acute myocardial infarction. Stent Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med 341:1949-1956.
22. Hobikoglu GF, Akyuz U, Akyuz F, et al. (2004) Factor V leiden is a risk factor for myocardial infarction in young Turkish men. Acta Cardiol 59:594-597.
23. Holm J, Hillarp A, Zö ller B, et al. (1999) Factor V Q506 (resistance to activated protein C) and prognosis after acute coronary syndrome. Thromb Haemost 81:857-860.
24. Holm J, Zoller B, Berntorp E, et al. (1996) Prevalence of factor V gene mutation amongst myocardial infarction patients and healthy controls is higher in Sweden than in other countries. J Intern Med 239:221-226.
25. Hudecek J, Dobrotová M, Hybenová J, et al. (2003) [Factor V Leiden and the Slovak population.] Vnitr Lek 49:845-850.
26. Inbal A, Freimark D, Modan B, et al. (1999) Synergistic effects of prothrombotic polymorphisms and atherogenic factors on the risk of myocardial infarction in young males. Blood 93: 2186-2190.
27. Juul K, Tybjaerg-Hansen A, Steffensen R, et al. (2002) Factor V Leiden: the Copenhagen City Heart Study and 2 meta-analyses. Blood 100:3-10.
28. Kim RJ, Becker RC (2003) Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: a meta-analysis of published studies. Am Heart J 146: 948-957.
29. Kontula K, Ylikorkala A, Miettinen H, et al. (1995) Arg506Gln factor V mutation (factor V Leiden) in patients with ischaemic cerebrovascular disease and survivors of myocardial infarction. Thromb Haemost 73:558-560.
30. Makris TK, Krespi PG, Hatzizacharias AN, et al. (2000) Resistance to activated protein C and FV leiden mutation in patients with a history of acute myocardial infarction or primary hypertension. Am J Hypertens 13(1 Pt 1):61-65.
31. Mansourati J, Da Costa A, Munier S, et al. (2000) Prevalence of factor V Leiden in patients with myocardial infarction and normal coronary angiography. Thromb Haemost 83:822-825.
32. Martini CH, Doggen CJ, Cavallini C, et al. (2005) No effect of polymorphisms in prothrombotic genes on the risk of myocardial infarction in young adults without cardiovascular risk factors. J Thromb Haemost 3:177-179.
33. Middendorf K, Gohring P, Huehns TY, et al. (2004) Prevalence of resistance against activated protein C resulting from factor V Leiden is significantly increased in myocardial infarction: investigation of 507 patients with myocardial infarction. Am Heart J 147:897-904.
34. Nicolaes GA, Dahlbäck B (2002) Factor V and thrombotic disease: description of a janus-faced protein. Arterioscler Thromb Vasc Biol 22:530-538 (review).
35. Petrovic D, Zorc M, Keber I, Peterlin B (2001) Joint effect of G1691A factor V point mutation and factor VII Arg/Gln(353) gene polymorphism on the risk of premature coronary artery disease. Ann Genet 44:33-36.
36. Pongrácz E, Tordai A, Csornai M, et al. (2003) [Significance of Factor V gene A506G mutation (Leiden) in the pathogenesis of ischemic stroke] Ideggyogy Sz 56:157-164.
37. Press RD, Bauer KA, Kujovich JL, Heit JA (2002) Clinical utility of factor V leiden (R506Q) testing for the diagnosis and management of thromboembolic disorders. Arch Pathol Lab Med 126:1304-1318 (review).
38. Prohaska W, Mannebach H, Schmidt M, et al. (1995) Evidence against heterozygous coagulation factor V 1691 G?A mutation with resistance to activated protein C being a risk factor for coronary artery disease and myocardial infarction. J Mol Med 73:521-524.
39. Pullmann R, Skerenová M, Lukác J, et al. (2004) Factor V Leiden and prothrombin G20210A mutations and the risk of atherothrombotic events in systemic lupus erythematosus. Clin Appl Thromb Hemost 10:233-238.
40. Redondo M,Watzke HH, Stucki I, et al. (1999) Coagulation factors II, V, VII, and X, prothrombin gene 20210G!A transition, and factor V Leiden in coronary artery disease. High factor V clotting activity is an independent risk factor for myocardial infarction. Arterioscler Thromb Vasc Biol 19:1020-1025.
41. Rees DC (1996) The population genetics of factor V Leiden (Arg506Gln) Br J Haematol 95:579-586 (review).
42. Ridker PM, Hennekens CH, Lindpaintner K, et al. (1995) Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 332:912-917.
43. Rosendaal FR, Siscovick DS, Schwartz SM, et al. (1997) Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood 89:2817-2821.
44. Rosendorff A, Dorfman DM (2007) Activated protein C resistance and factor V Leiden: a review. Arch Pathol Lab Med 131:866-871.
45. Rosing J, Tans G (1997) Coagulation factor V: an old star shines again. Thromb Haemost 78:427-433 (review).
46. Samaha M, Trossaert M, Conard J, et al. (1995) Prevalence and patient profile in activated protein C resistance. Am J Clin Pathol 104:450-454.
47. Segev A, Ellis MH, Segev F, et al. (2005) High prevalence of thrombophilia among young patients with myocardial infarction and few conventional risk factors. Int J Cardiol 98:421-424.
48. Seligsohn U, Lubetsky A (2001) Genetic susceptibility to venous thrombosis. N Engl J Med 344:1222-1231 (review).
49. Settin A, Dowaidar M, El-Baz R, et al. (2008) Frequency of factor V Leiden mutation in Egyptian cases with myocardial infarction. Hematology 13:170-174.
50. Tanis BC, Bloemenkamp DG, van den Bosch MA, et al. (2003) Prothrombotic coagulation defects and cardiovascular risk factors in young women with acute myocardial infarction. Br J Haematol 122:471-478.
51. Taymaz H, Erarslan S, Oner ET, et al. (2007) Sequence variations within the genes related to hemostatic imbalance and their impact on coronary artery disease in Turkish population. Thromb Res 119:55-62.
52. Vallus G, Dlustus B, Acsady G, et al. (2007) Factor V Leiden and apolipoprotein E genotypes in severe femoropopliteal atherosclerosis with restenosis. Clin Chim Acta 377:256-260.
53. van Bockxmeer FM, Baker RI, Taylor RR. (1995) Premature ischaemic heart disease and the gene for coagulation factor V. Nat Med 1(3):185.
54. Van de Water NS, French JK, Lund M, et al. (2000) Prevalence of factor V Leiden and prothrombin variant G20210A in patients age <50 years with no significant stenoses at angiography three to four weeks after myocardial infarction. J Am Coll Cardiol 36:717-722.
55. van der Bom JG, Bots ML, Haverkate F, et al. (1996) Reduced response to activated protein C is associated with increased risk for cerebrovascular disease. Ann Intern Med 126:832-833.
56. Varga EA (2008) Genetic counseling for inherited thrombophilias. J Thromb Thrombolysis 25(1):6-9.
57. Weischer M, Juul K, Zacho J, et al. (2010) Prothrombin and risk of venous thromboembolism, ischemic heart disease and ischemic cerebrovascular disease in the general population. Atherosclerosis 208(2):480-483.
58. Yanqing H, Fangping C, Qinzhi X, et al. (2003) No association between thrombosis and factor V gene polymorphisms in Chinese Han population. Thromb Haemost 89:446-451.
59. Ye Z, Liu EH, Higgins JP, et al. (2006) Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66,155 cases and 91,307 controls. Lancet 367:1729-1730.
60. Zee RY, Cook NR, Cheng S, et al. (2006) Multi-locus candidate gene polymorphisms and risk of myocardial infarction: a population-based, prospective genetic analysis. J Thromb Haemost 4:341-348.